The seroepidemiology of measles in Western Europe

The European Regional Office of WHO has targeted measles for elimination from the region in 2007. Large national, age and sex stratified serological surveys of measles antibody were conducted in seven Western European countries from 1994–8 as part of the European Sero-epidemiology Network. Three patterns were observed in the country-specific measles seroprofiles, ranging from (very) low susceptibility (four countries) to high susceptibility (one country). Susceptibility levels amongst 2–4-year-olds ranged from 2·9 to 29·8 %, in 5–9-year-olds from 2·5 to 25 % and 10–19-year-olds from 2·1 % to 13·9 %. A country's susceptibility profile was highly associated with vaccine coverage for the first dose. First dose coverage ranged from 91 to 97·5 % for low susceptibility countries, 75 to 85 % for intermediate susceptibility countries and 55 % for the high susceptibility country. Only the high susceptibility country still reports epidemic measles. In low susceptibility countries, which have achieved or are very close to measles elimination, the priority will be to maintain high MMR vaccine coverage in all geopolitical units for both vaccine doses. In moderate susceptibility countries there is still some endemic transmission, but also risk of outbreaks as pools of susceptibles accumulate. In the high susceptibility country the priority will be to increase infant vaccine coverage and reduce regional variation in coverage levels.

France | Finland. | J. Schellekens | H. D. de Melker | M. Kretzschmar | W. Edmunds | S. Salmaso | S. Baron | R. Pebody | D. Levy-bruhl | C. von Hunolstein | D. Altmann | Sweden. | P. Leinikki | S. van den Hof | A. Plesner | A. Tischer | G. Berbers | P. Crovari | G. Gabutti | P. Saliou | E. Miller | H. Hallander | S. Swidsinski | P Morgan-Capner | O. Chappey | E Miller | S Salmaso | W J Edmunds | R G Pebody | A. Anemona | I Davidkin | M Valle | P. Olin | A. Siedler | M. C. Conyn-van Spaendonck | A. Giammanco | P Saliou | H de Melker | D Lévy-Bruhl | M C Rota | S van den Hof | G Berbers | Spaendonck MCV | P Crovari | G Gabutti | L Hesketh | A M Plesner | M Raux | A Tische | L. Magnius | I. Davidkin | H. Aggerbeck | L. Hesketh | H. Wachmann | I. Davidkin | Chris Hesketh | M. Valle | U. Rudén | M. Ljungman | T. Marzec | D. Valle | P. Crovari | C. Blondeau | E. Gerike | E. Bonin | M. Raux | Daniel Le | C. Giordano | David Andrews | P. Morgan‐Capner | Mervi Eerola | A. Tischer | Peter Osborne | Italy. | P. Brown | M. Rota | A. Tische | M. C. Rota | J. Lindback | A. Malet | S. Hof | Doi | G. Berbers | De Melker | H. Pebody | Rg Edmunds | Wj Levy-Bruhl | H. Melker | D. Le ! Vy-Bruhl | M. Conyn- Spaendonck | Blenda Bo $ Ttiger | Henrik Grauballe | Anne-Marie Westh | Tove Plesner | Nils Strandberg Rønne | Henrik Pedersen | Nick Westh | Nigel Farrington | Louise Gay | Elizabeth Maple | Kate Miller | Mary Morgan-Capner | G Ramsay | Rose-Marie O $ Lander | Franc Oise Fievet-Groyne | Vy-Bruhl | Isabelle Rebie 're ; Germany | Doi

[1]  J. V. Steenbergen,et al.  Measles outbreak--Netherlands, April 1999-January 2000. , 2000, MMWR. Morbidity and mortality weekly report.

[2]  K. Markvart,et al.  [Frequency of complications in measles]. , 1968, Ceskoslovenska pediatrie.

[3]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[4]  T. Hovi,et al.  No measles in Finland , 1997, The Lancet.

[5]  F. Cutts,et al.  Successes and failures in measles control. , 1994, The Journal of infectious diseases.

[6]  I Davidkin,et al.  Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. , 1998, Vaccine.

[7]  S. Salmaso,et al.  Infant immunization coverage in Italy: estimates by simultaneous EPI cluster surveys of regions. ICONA Study Group. , 1999, Bulletin of the World Health Organization.

[8]  L. Sehulster,et al.  Measles outbreak in a fully immunized secondary-school population. , 1987, The New England journal of medicine.

[9]  Paul F. Grassby,et al.  The role of the pharmacist in diabetes care: The Forum of National Pharmaceutical Associations and the World Health Organisation Regional Office for Europe , 2000 .

[10]  E. Talsma,et al.  The effects of vaccination, the incidence of the target diseases , 1998 .

[11]  M. Valenciano,et al.  ESEN: a comparison of vaccination programmes - Part three : measles mumps and rubella. , 1998, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  D. Miller Frequency of Complications of Measles, 1963 , 1964 .

[13]  J. Weinberg,et al.  The European Sero-Epidemiology Network. , 1997, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  K. Cantell,et al.  The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. , 1994, The New England journal of medicine.

[15]  R. Pebody,et al.  The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella , 2000, Epidemiology and Infection.

[16]  D. Shepard Economic analysis of investment priorities for measles control. , 1994, The Journal of infectious diseases.

[17]  Progress toward global measles control and regional elimination, 1990-1997. , 1998, MMWR. Morbidity and mortality weekly report.

[18]  E. L. Miller,et al.  The sero-epidemiology of diphtheria in Western Europe , 2000, Epidemiology and Infection.

[19]  Measles outbreak, Netherlands. , 2000, Releve epidemiologique hebdomadaire.